{
    "organizations": [],
    "uuid": "4e8fd01e303a145bb4965fd52a068daed537bb40",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-galmed-announces-arrive-study-data/brief-galmed-announces-arrive-study-data-idUSFWN1Q413U",
    "ord_in_thread": 0,
    "title": "BRIEF-Galmed Announces Arrive Study Data",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 14 (Reuters) - Galmed Pharmaceuticals Ltd:\n* GALMED ANNOUNCES ARRIVE STUDY DATA * TOP-LINE RESULTS FROM ARRIVE TRIAL DID NOT MEET ITS PRIMARY ENDPOINT\n* ANNOUNCED TOP-LINE RESULTS FROM ARRIVE TRIAL, WHICH DID NOT MEET ITS PRIMARY ENDPOINT\n* TOPLINE DATA FROM GALMEDâ€˜S PHASE IIB ARREST STUDY IS EXPECTED IN Q2 2018 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-14T20:12:00.000+02:00",
    "crawled": "2018-02-15T20:15:34.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "galmed",
        "pharmaceutical",
        "ltd",
        "galmed",
        "announces",
        "arrive",
        "study",
        "data",
        "result",
        "arrive",
        "trial",
        "meet",
        "primary",
        "endpoint",
        "announced",
        "result",
        "arrive",
        "trial",
        "meet",
        "primary",
        "endpoint",
        "topline",
        "data",
        "galmed",
        "phase",
        "iib",
        "arrest",
        "study",
        "expected",
        "q2",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}